At the time, the pharmaceutical company Pfizer started a research program to develop a selective PDE5 inhibitor to increase the nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) pathway for the treatment of angina. This evidence concerns the gene PDE5A and angina pectoris.